Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
A holder of Laboratory Corporation of America Holdings (LH) common stock has filed a Rule 144 notice to sell 87 shares through Fidelity Brokerage Services on the NYSE, with an approximate sale date of 02/12/2026 and an aggregate market value of $25,266.54.
The 87 shares were acquired on 02/11/2026 via restricted stock vesting from the issuer as compensation. In the past three months, Jonathan Meltzer sold LH common stock in two transactions: 88 shares on 02/09/2026 for $24,246.64 and 91 shares on 02/10/2026 for $25,187.89.
An insider has filed a Form 144 notice indicating an intention to sell up to 5,273 shares of common stock, with an aggregate market value of $1,499,535.74. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/11/2026.
The securities to be sold were acquired via restricted stock vesting from the issuer on 02/02/2024 (361 shares) and 03/27/2024 (4,912 shares), as compensation. The notice also lists a prior sale of 5,745 shares of common stock on 11/11/2025 for gross proceeds of $1,509,498.75.
Labcorp Holdings Inc. director John H. Sampson filed an initial ownership report on Form 3. The filing states that no securities of Labcorp Holdings Inc. are beneficially owned. The report is filed as a single reporting person in the capacity of director.
Labcorp Holdings Inc. (LH) Chief Financial Officer and EVP Julia Aijun Wang reported equity compensation activity on February 6, 2026. 893 Restricted Stock Units vested and converted into 893 shares of common stock, consistent with a multi-year vesting schedule that began on February 6, 2025.
To cover tax withholding obligations, 254 of these shares were withheld at a price of $277.2 per share, leaving 1,202.239 shares of common stock beneficially owned directly after the transactions. Wang also directly holds 3,474 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP, President of Enterprise Diagnostics, CMO and CSO, reported multiple equity transactions tied to vested restricted stock units. On February 6 and 7, 2026, a total of 670, 517 and 111 restricted stock units converted into the same number of Labcorp common shares at an exercise price of $0 per share. Shares were then withheld on February 6 and 9, 2026 to cover tax obligations, including 209 shares at $277.2 per share and 148 and 32 shares at $274.01 per share. After these transactions, Caveney directly owned 31,077.9234 Labcorp common shares, and 2,890 restricted stock units remained outstanding.
Labcorp Holdings Inc. executive Akinbolade Oyegunwa, EVP, CIO & CTO, reported routine equity compensation activity. On February 6 and 7, 2026, restricted stock units (RSUs) covering 180 and 149 shares of common stock, respectively, were converted into Labcorp common shares.
To cover tax withholding obligations, a total of 112 common shares were withheld, at prices of $277.2 and $274.01 per share. Following these transactions, Oyegunwa directly held 3,944.253 shares of common stock and 1,610 RSUs, each RSU representing the right to receive one share of common stock as they vest over the disclosed schedules.
Labcorp Holdings Inc. President & CEO Adam H. Schechter reported multiple equity transactions. On February 6 and 7, 2026, he exercised restricted stock units, converting 4,460 and 3,249 RSUs into an equal number of common shares at an exercise price of $0 per share. Related grants vest in three equal annual installments beginning on February 6, 2025 and February 7, 2024.
To cover tax withholding, Schechter had 1,315 shares withheld at $277.20 on February 6, 2026 and 1,352 shares withheld at $274.01 on February 9, 2026. After these transactions, he directly held 92,616 shares of common stock and 18,679 restricted stock units.
Labcorp Holdings Inc. executive Peter J. Wilkinson, SVP and Chief Accounting Officer, reported multiple equity award transactions. On February 6 and 7, 2026, Restricted Stock Units (RSUs) vested and were converted into 133 and 134 shares of common stock, respectively, each RSU representing one share.
To cover tax withholding obligations related to these vestings, 45 shares at $277.20 per share on February 6 and 46 shares at $274.01 per share on February 9 were withheld. After these transactions, Wilkinson directly held 2,028.2194 shares of Labcorp common stock and 2,224 RSUs in total.
Labcorp Holdings Inc. executive Mark S. Schroeder, EVP, President Diagnostics & COO, reported multiple equity compensation events in early February 2026. On February 6–7, 2026, a total of 1,424 Restricted Stock Units converted into an equal number of common shares at a stated price of $0 per share, reflecting vesting of prior awards.
To cover tax withholding obligations, the company withheld 239 common shares at $277.2 on February 6 and 166 and 53 common shares at $274.01 on February 9, as indicated by transaction code “F” and the tax footnote. After these transactions, Schroeder directly held 5,926.1426 common shares and 3,164 Restricted Stock Units, each RSU representing the contingent right to receive one Labcorp common share.
Labcorp Holdings Inc. executive Sandra D. van der Vaart, EVP Corporate Affairs, reported multiple stock transactions involving restricted stock units (RSUs) and related tax withholding. On February 6, 2026, 387 RSUs were converted into the same number of Labcorp common shares at an exercise price of $0, and 101 shares were disposed of at $277.20 per share to cover tax withholding, leaving 2,589.4864 common shares directly owned. On February 7, 2026, a further 353 RSUs were converted into common stock at $0, increasing direct ownership to 2,942.4864 shares. On February 9, 2026, 93 shares were disposed of at $274.01 per share for tax withholding, with 2,849.4864 common shares held directly afterward. The filing shows 1,870 RSUs held after the February 6 transaction and 1,517 RSUs after the February 7 transaction, each RSU representing the right to receive one Labcorp common share. The share totals include 29.8173 shares acquired under the company’s 2025 Employee Stock Purchase Plan.